Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia

被引：0
|
作者：
Yu-he Wu
Hai-yan Xiao
Ri-cheng Quan
Xu-dong Tang
Wei-yi Liu
Yan Lyu
Zhuo Chen
Chi Liu
Xiao-mei Hu
机构：
[1] China Academy of Chinese Medical Sciences,Department of Hematology, Xiyuan Hospital
[2] China Academy of Chinese Medical Sciences,Graduate School
来源：
Chinese Journal of Integrative Medicine | 2023年 / 29卷
关键词：
acute myeloid leukemia; elderly; Qinghuang Powder; low-intensity chemotherapy; Chinese medicine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：832 / 837
页数：5
相关论文
共 50 条
  • [31] At-Home Care Program for Acute Myeloid Leukemia Induction Phase in Patients Treated with Venetoclax-Based Low-Intensity Regimens
    Martinez-Roca, Alexandra
    Jimenez-Vicente, Carlos
    Merchan, Beatriz
    Castano-Diez, Sandra
    Zugasti, Ines
    Brillembourg, Helena
    Bataller, Alex
    Guijarro, Francesca
    Cortes-Bullich, Albert
    Trigueros, Ana
    Perez-Valencia, Amanda Isabel
    Gallego, Cristina
    Ballestar, Nuria
    Rodriguez-Lobato, Luis Gerardo
    Carcelero, Esther
    Diaz-Beya, Marina
    Esteve, Jordi
    Fernandez-Aviles, Francesc
    CANCERS, 2024, 16 (24)
  • [32] Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia
    Maurillo, Luca
    Buccisano, Francesco
    Spagnoli, Alessandra
    Voso, Maria Teresa
    Fianchi, Luana
    Papayannidis, Cristina
    Gaidano, Gian Luca
    Breccia, Massimo
    Musto, Pellegrino
    De Bellis, Eleonora
    Del Principe, Maria Ilaria
    Lunghi, Monia
    Lessi, Federica
    Martinelli, Giovanni
    Venditti, Adriano
    ANNALS OF HEMATOLOGY, 2018, 97 (10) : 1767 - 1774
  • [33] Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia
    Luca Maurillo
    Francesco Buccisano
    Alessandra Spagnoli
    Maria Teresa Voso
    Luana Fianchi
    Cristina Papayannidis
    Gian Luca Gaidano
    Massimo Breccia
    Pellegrino Musto
    Eleonora De Bellis
    Maria Ilaria Del Principe
    Monia Lunghi
    Federica Lessi
    Giovanni Martinelli
    Adriano Venditti
    Annals of Hematology, 2018, 97 : 1767 - 1774
  • [34] Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
    Hui Liu
    Rong Fu
    Lijuan Li
    Guojin Wang
    Jia Song
    Erbao Ruan
    Huaquan Wang
    Yuhong Wu
    Xiaoming Wang
    Kai Ding
    Zonghong Shao
    Clinical Drug Investigation, 2017, 37 : 167 - 174
  • [35] Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients
    Milica Colovic
    Natasa Colovic
    Milica Radojkovic
    Dejana Stanisavljevic
    Nada Kraguljac
    Gradimir Jankovic
    Dragica Tomin
    Nada Suvajdzic
    Ana Vidovic
    Henry Dushan Atkinson
    Annals of Hematology, 2012, 91 : 1363 - 1370
  • [36] Genetic features and efficacy of decitabine-based chemotherapy in elderly patients with acute myeloid leukemia
    Wang, Bianhong
    Guan, Wei
    Lv, Na
    Li, Ting
    Yu, Fan
    Huang, Yuehua
    Wang, Yanying
    Li, Lihong
    Yu, Li
    HEMATOLOGY, 2021, 26 (01) : 371 - 379
  • [37] Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients
    Colovic, Milica
    Colovic, Natasa
    Radojkovic, Milica
    Stanisavljevic, Dejana
    Kraguljac, Nada
    Jankovic, Gradimir
    Tomin, Dragica
    Suvajdzic, Nada
    Vidovic, Ana
    Atkinson, Henry Dushan
    ANNALS OF HEMATOLOGY, 2012, 91 (09) : 1363 - 1370
  • [38] A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
    Andrew F. Berdel
    Raphael Koch
    Joachim Gerss
    Marcus Hentrich
    Rudolf Peceny
    Tobias Bartscht
    Björn Steffen
    Marina Bischoff
    Karsten Spiekermann
    Linus Angenendt
    Jan-Henrik Mikesch
    Tobias Kewitz
    Trude Butterfass-Bahloul
    Hubert Serve
    Georg Lenz
    Wolfgang E. Berdel
    Utz Krug
    Christoph Schliemann
    Annals of Hematology, 2023, 102 : 63 - 72
  • [39] A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
    Berdel, Andrew F.
    Koch, Raphael
    Gerss, Joachim
    Hentrich, Marcus
    Peceny, Rudolf
    Bartscht, Tobias
    Steffen, Bjoern
    Bischoff, Marina
    Spiekermann, Karsten
    Angenendt, Linus
    Mikesch, Jan-Henrik
    Kewitz, Tobias
    Butterfass-Bahloul, Trude
    Serve, Hubert
    Lenz, Georg
    Berdel, Wolfgang E.
    Krug, Utz
    Schliemann, Christoph
    ANNALS OF HEMATOLOGY, 2023, 102 (01) : 63 - 72
  • [40] Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patients
    Muresan, Bogdan
    Mamolo, Carla
    Cappelleri, Joseph C.
    Mokgokong, Ruth
    Palaka, Athina
    Soikkeli, Fanni
    Heeg, Bart
    FUTURE ONCOLOGY, 2021, 17 (22) : 2883 - 2892
12345